Business Context and Reporting Period
This Form 8-K is a current report filed by Sunshine Heart, Inc. on October 29, 2013. The filing serves as a Regulation FD disclosure regarding the presentation of initial clinical results for the Company's C-Pulse System. The data presented stems from the OPTIONS HF EU trial and was delivered at the Transcatheter Therapeutics 2013 (TCT) conference in San Francisco, California, between October 27 and November 1, 2013.
Key Financial Metrics
The filing text does not provide specific financial data. There are no disclosures regarding revenue, profit, cash flow, margins, debt, or liquidity in this document. The report focuses exclusively on clinical trial updates and regulatory disclosure.
Material Changes
No material financial changes versus prior periods are reported. The material event disclosed is the release of initial clinical study results for the C-Pulse System, which represents a significant operational milestone rather than a financial variance.
Guidance, Outlook, and Risks
- Management Commentary: The Company announced that Professor Thomas Krabatsch, Andrew Kao, M.D., and Dr. William Cohn presented initial results from the OPTIONS HF EU trial.
- Outlook: The filing indicates that presentation materials and a press release are available on the Company's Investor Relations website.
- Risks and Contingencies: The filing includes a standard limitation of incorporation by reference, stating that the information furnished under Item 7.01 is not "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and shall not be deemed an admission as to the materiality of information required solely by Regulation FD.
Investor Verification Checklist
- Verify the specific clinical outcomes and statistical significance of the OPTIONS HF EU trial by reviewing the attached Exhibits 99.1 through 99.4.
- Confirm the regulatory status of the C-Pulse System following the presentation of these initial results.
- Review the Company's website (http://www.sunshineheart.com) for the full text of the press release and presentation slides referenced in the filing.
- Note that this filing contains no financial statements; investors should refer to the most recent 10-K or 10-Q for financial health metrics.